It's a Windhover statistic that Roger Longman noted in passing during a dealmaking presentation--if they have a list, I'm sure it's for sale. I don't have it or need it.
One interesting likelihood--venture capital that usually goes into private firms will be increasingly diverted to investments in public microcaps--but as was described today, the terms will be "ugly."
There is no simple answer to the financing issue--it was discussed and debated all morning--with people from Big Pharma, midsize pharma, and VCs all participating.
I'm not worried about Cortex's ability to handle negotiations with Big Pharma.
NeuroInvestment
Market Data 
Markets 
AI
